Abstract: Disclosed is an amplification circuit, which includes a first amplifier that receives an external signal and performs first band pass filtering on the external signal to output a first filter signal, and a second amplifier that receives the first filter signal and performs second band pass filtering on the first filter signal to output a second filter signal, and a frequency pass bandwidth of the second band pass filtering is narrower than a frequency pass bandwidth of the first band pass filtering.

Abstract: A hybrid communication device, an operation method thereof, and a communication system including the same are provided. The hybrid communication device includes a contact unit that includes an antenna for receiving a first communication signal and an electrode for receiving a second signal, a switch controller that includes a first switch and a second switch and controls the first switch and the second switch based on a change in capacitance of the electrode, and a signal processing unit that receives at least one of the first communication signal and the second communication signal from the contact unit via the first switch and processes the received signal. The first switch is connected to the contact unit, and the signal processing unit is connected to the first switch.

Abstract: The present invention relates to a strain having liver function improving activity, and a use thereof. Specifically, the present invention relates to a health food composition for improving liver function and a pharmaceutical composition for improving liver function, which contain, as an active ingredient, one or more strains selected from the group consisting of a Lactobacillus pentosus KF8 (accession number KCCM11997P) strain, a Bacillus subtilis KF11 (accession number KCCM11981P) strain, and a Lactococcus lactis KF140 (accession number KCCM11673P) strain, a lysate thereof or a culture product thereof.

Abstract: The present invention relates to a composition for inhibiting non-fluorescent advanced glycation end products, and a use thereof. More specifically, the present invention relates to: a composition for inhibiting non-fluorescent advanced glycation end products, comprising one or more strains selected from the group consisting of Lactobacillus sp. strains, Lactococcus sp. strains, Enterococcus sp. strains, Bifidobacterium sp. strains, Bacillus sp. strains, Saccharomyces sp. strains, Pediococcus sp. strains, and Leuconostoc sp. strains; and a food composition, a pharmaceutical composition, a composition for intestinal regulation, a probiotic composition, a feed composition, and a fermented product, which have an activity of reducing non-fluorescent advanced glycation end products and comprise the composition. In addition, the present invention relates to a method for producing a non-fluorescent advanced glycation end product inhibitor and a method for inhibiting non-fluorescent advanced glycation end products.

Abstract: The present invention relates to a prebiotic composition, a composition for improving gut microorganisms, a composition for improving gut health or gut function, a composition for alleviating, preventing, or treating inflammatory bowel disease or leaky gut syndrome, or a composition for alleviating, preventing, or treating obesity or metabolic disease, which each comprise a molokhia extract or a molokhia polymer fraction as an active ingredient to induce the proliferation of beneficial intestinal bacteria and to improve, prevent, or treat gut heath or gut function. In addition, the composition comprising a molokhia extract or a molokhia polymer fraction as an active ingredient can alleviate, prevent, or treat bowel disease or leaky gut syndrome.

Abstract: The present invention relates to a novel strain having the activity of reducing advanced glycation end products and a use thereof and, more particularly, to a food composition having the activity of reducing advanced glycation end products and a pharmaceutical composition for preventing or treating a disease caused by advanced glycation end products each of which comprises a Lactococcus lactis KF140 (accession number KCCM11673P) strain, a Bacillus subtilis KF11 (accession number KCCM11981P) strain, a Lactobacillus pentosus KF8 (accession number KCCM11997P) strain, or a Lactobacillus paracasei KF00816 (accession number KCCM11998P) strain, which are all novel strains; a lysate thereof; or a culture thereof as an active ingredient.